5 Common Mistakes That Can Slow Baby Development And What to Do Instead
It's easy to overthink baby development. With so many toys, classes, and milestone trackers out there, it can feel like you need to follow every program or get everything 'just right.' But babies don't need perfection to thrive. What they need is the opportunity to move, explore, connect, and feel safe.
That said, there are a few common habits that might unintentionally hold back their development. They're all fixable, and knowing what to tweak can help your baby grow with more confidence (and less pressure on you).
1. Relying too much on baby gear.
Swings, bouncers, and loungers have their place, especially when you need two hands. But when babies spend too much time in gear, it limits their opportunities to build essential muscle strength in their neck, shoulders, and core. Those muscles are key for rolling, crawling, and eventually walking.
What to try instead:
Aim for short, frequent bursts of tummy time throughout the day.
Start tummy time on your chest and or with a small rolled towel under your baby's chest if they're resistant at first.
Use a floor mirror to encourage them to lift their head and engage their core.
Try side-lying play as a bridge to rolling.
Keep baby gear short and balanced. No more than 20-30 minutes at a time.
2. Skipping floor time and free movement.
The floor is where development takes off. When babies have the space to move freely by reaching, scooting, and stretching, they're not just working on gross motor skills. They're building spatial awareness, coordination, and the ability to problem-solve through trial and error.
Ways to boost their floor play:
Place toys just out of reach to motivate rolling and reaching.
Create a safe 'yes space' with soft mats and minimal barriers.
Use high-contrast toys early on and gradually introduce textured items for sensory play.
3. Missing out on face-to-face interaction.
Your face is your baby's favorite thing to look at. These moments of eye contact, silly expressions, and back-and-forth sounds are powerful. They lay the foundation for language, emotional intelligence, and connection.
Simple ways to build in more connection:
Talk through your everyday routines like diaper changes, feedings, and walks outside.
Imitate your baby's coos and sounds to encourage back-and-forth communication.
Play peek-a-boo or simple interactive games.
Use exaggerated expressions. Babies love animated faces!
4. Focusing only on physical milestones.
It's easy to zero in on when your baby rolls, crawls, or sits up, but emotional development matters just as much. From the beginning, babies learn about trust, safety, and connection through how we respond to their cues. Every moment of comfort, eye contact, and gentle tone helps build a sense of emotional security.
Try these emotionally supportive strategies:
Babywearing and skin-to-skin contact for closeness and comfort.
Predictable routines that help your baby feel secure.
Reading books with emotional expressions and varied tones of voice.
Singing, humming, or simply talking to your baby. They're drawn to your voice.
Offering a calm, reassuring presence during fussier moments.
There's no one 'right' way to connect. What matters most is being responsive in a way that feels natural for both of you.
5. Using screens too early.
When you're home with a baby, screen time can be tempting. But for babies under one year, passive viewing doesn't offer the same developmental benefits as real-life interaction. It can also take time away from essential activities like movement, play, and connection.
Alternatives to screen time:
Play music and have a little dance party–babies love rhythm and movement.
Offer sensory bins or safe household items to explore different textures.
Read interactive books with flaps, mirrors, or bold images.
Let your baby watch you go about your day while narrating what you're doing.
Video chatting with loved ones is the exception; it's interactive and can help strengthen social bonds. The key is keeping screen time purposeful and limited in the early months.
What to dive deeper into screen time and how it affects development? Check out this PedsDocTalk YouTube video that explains more.
Final thoughts
You don't need to be perfect or follow a strict plan to support your baby's development. What matters most is being present, tuned in, and offering opportunities for connection and movement throughout the day.
By making a few small adjustments, like limiting baby gear, encouraging floor time, and reading books together, you're helping your baby build the foundation for lifelong skills. These small shifts add up.
Development in the first year isn't about hitting every milestone early; it's about creating an environment where your baby feels safe, supported, and ready to explore at their own pace.
Curious about which milestones to watch for in your baby's first year? Check out the free PedsDocTalk Milestones to Monitor guide. It offers a clear, supportive look at what to expect and when to check in with your child's pediatrician, without the pressure.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO, July 22, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. "As with the recent announcement of the award of our patent in China, this Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives," said Maria Zannes, President and CEO of bioAffinity Technologies. Lung cancer is the leading cause of cancer death in Canada, according to the Canadian Cancer Society. In 2024, approximately 31,000 Canadians were diagnosed with lung cancer, and approximately 20,700 people died of the disease. More than 70% of the lung cancer deaths were linked to smoking. "We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath® Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science," Ms. Zannes said. "Recent case studies highlight CyPath Lung's ability to detect lung cancer at its earliest stages, making our test all the more valuable in Canada where 50% of all lung cancer cases are diagnosed late at Stage IV with the five-year survival rate overall of about 19% in Canada, according to government statistics." The Canadian patent (Patent No. 3,136,245) – titled "System and Method for Determining Lung Health" – protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum. CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. About CyPath® Lung CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath® Lung in Canada. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath® Lung in Canada, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. View source version on Contacts bioAffinity Technologies Julie Anne OvertonDirector of Communicationsjao@ Investor Relations Dave GentryRedChip Companies Inc.1-800-RED-CHIP (733-2447) or 407-491-4498BIAF@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings
July 22 - UnitedHealth Group (NYSE:UNH) has tumbled roughly 42% year?to?date, driven by rising Medicare Advantage costs, a surprise CEO exit, withdrawn guidance and a Department of Justice probe. However, ahead of its July 29 Q2 earnings, Bernstein analyst Lance Wilkes tapped UNH as a 'Top Pick,' saying the pullback creates an attractive entry point. He noted the stock trades at about 13.5 times forward earnings, below its ten?year average. Warning! GuruFocus has detected 4 Warning Sign with UNH. Wilkes cut his 2025 EPS estimate by 10% to reflect reserve strengthening and cost pressures in individual and Medicaid segments, plus a cleanup of OptumHealth risk contracts. Yet he projects earnings per share could double by 2029, implying a 19% compound annual growth rate. The analyst expects cost normalization to begin in Medicaid in Q3 and in Medicare Advantage in early 2026 as utilization patterns stabilize. He also highlighted a hardening pricing environment for government managed?care plans as a margin tailwind. Is UNH Stock a Buy? Based on the one year price targets offered by 24 analysts, the average target price for UnitedHealth Group Inc is $375.46 with a high estimate of $677.00 and a low estimate of $270.00. The average target implies a upside of +33.08% from the current price of $282.14. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025
MINNEAPOLIS, July 22, 2025--(BUSINESS WIRE)--Sleep Number Corporation (Nasdaq: SNBR) will release its fiscal second quarter results through June 28, 2025, before market open on Wednesday, July 30, 2025. Management will host its regularly scheduled conference call to discuss the company's results at 8:30 a.m. EDT (7:30 a.m. CDT; 5:30 a.m. PDT). To access the webcast, please visit the investor relations area of the Sleep Number website at The webcast replay will remain available for approximately 60 days. About Sleep Number Corporation Sleep Number is a sleep wellness company. We are guided by our purpose to improve the health and wellbeing of society through higher quality sleep. To date, our innovations have improved nearly 16 million lives. Our sleep wellness platform helps solve sleep problems, whether it's providing individualized temperature control for each sleeper through our Climate360 smart bed or applying our 34 billion hours of longitudinal sleep data and expertise to research with global institutions. Our smart bed ecosystem helps people sleep better by offering adjustable comfort and personalized sleep and health insights. Millions of Smart Sleepers benefit from higher quality sleep, and our 3,400 dedicated team members are passionate about creating innovative solutions through our vertically integrated business model, including direct-to-consumer selling in 630 stores and online. To learn more about life-changing, individualized sleep, visit a Sleep Number® store near you, our newsroom and investor relations sites, or View source version on Contacts Investor Contact investorrelations@ Media Contact Muriel Lussier, Sleep Number Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data